Mutations in PRKN and SNCA genes important for the progress of Parkinson's disease

Current Genomics

Volumn 14, Issue 8, 2013, Pages 502-517

  Oczkowska, Anna ^a   Kozubski, Wojciech ^a   Lianeri, Margarita ^a   Dorszewska, Jolanta ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Alpha synuclein; Parkin; Parkinson's disease; PRKN; SNCA

Indexed keywords

ALPHA SYNUCLEIN; DOPAMINE; HEXOKINASE 1; LEVODOPA; PARKIN; REACTIVE OXYGEN METABOLITE;

ALLELE; APOPTOSIS; ARTICLE; CHROMOSOME 6; CHROMOSOME DELETION; CLINICAL FEATURE; DYSKINESIA; GENE; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC POLYMORPHISM; HUMAN; META ANALYSIS; MISSENSE MUTATION; MOTOR PERFORMANCE; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; POINT MUTATION; PRKN GENE; SNCA GENE; UBIQUITINATION;

EID: 84894092157     PISSN: 13892029     EISSN: 18755488     Source Type: Journal    
DOI: 10.2174/1389202914666131210205839     Document Type: Article

References (190)

1. Dorsey, E.R.; Constantinescu, R.; Thompson, J.P.; Biglan, K.M.; Holloway, R.G.; Kieburtz, K.; Marshall, F.J.; Ravina, B.M.; Schifitto, G.; Siderowf, A.; Tanner, C.M. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology, 2007, 68, 384-386.
2. De Lau, L. M; Breteler, M.M. Epidemiology of Parkinson's disease. Lancet. Neurol., 2006, 5, 525.
3. Friedman, A. Parkinsons Disease-mechanisms, diagnostic, treatment. Czelej, Warsaw 2005.
4. Del Tredici, K.; Rüb, U.; De Vos, R.A.; Bohl, J.R.; Braak, H. Where does parkinson disease pathology begin in the brain? J. Neuropathol. Exp. Neurol., 2002, 61, 413.
5. Hornykiewicz, O. The discovery of dopamine deficiency in the parkinsonian brain. J. Neural. Transm., 2006, 70, 9-15.
6. Maroteaux, L.; Campanelli, J.T.; Scheller, R.H. Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J. Neurosci., 1988, 8, 2804-2815.
7. Golbe, L.I.; Di Ioro, G.; Bonavita, V.; Miller, D.C.; Duvoisin, R.C. A large kindred with autosomal dominant Parkinson's disease. Ann. Neurol., 1990, 27, 276.
8. Hattori, N.; Kitada, T.; Matsumine, H.; Asakawa, S.; Yamamura, Y.; Yoshino, H.; Kobayashi, T.; Yokochi, M.; Wang, M.; Yoritaka, A.; Kondo, T.; Kuzuhara, S.; Nakamura, S.; Shimizu, N.; Mizuno, Y. Molecular genetic analysis of a novel parkin gene in Japanese families with autosomal recessive juvenile parkinsonism: evidence for variable homozygous deletions in the parkin gene in affected individuals. Ann. Neurol., 1998, 44, 935-941.
9. Clayton, D.F.; George, J.M. The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease. Trends. Neurosci., 1998, 21, 249.
10. Recchia, A.; Debetto, P.; Negro, A.; Guidolin, D.; Skaper, S.D.; Giusti, P. Alpha-synuclein and Parkinson's disease. FASEB J., 2004, 18, 617-626.
11. Bartels, T.; Choi, J.G.; Selkoe, D.J. α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature, 2011, 14, 107.
12. Totterdell, S.; Meredith, G.E. Localization of alpha-synucleinto identified fibers and synapses in the normal mouse brain. Neuroscience, 2005, 135, 907-913.
13. Alim, M.A.; Hossain, M.S.; Arima, K.; Takeda, K.; Izumiyama, Y.; Nakamura, M.; Kaji, H.; Shinoda, T.; Hisanaga, S.; Ueda, K. Tubulin seeds alpha-synuclein fibril formation. J. Biol. Chem., 2002, 277, 2112.
14. Cole, N.B.; Murphy, D.D.; Grider, T.; Rueter, S.; Brasaemle, D.; Nussbaum, R.L. Lipid droplet binding and oligomerization properties of the Parkinson's disease protein α-synuclein. J. Biol. Chem., 2002, 277, 6344.
15. Mak, S.K.; McCormack, A.L.; Langston, J.W. Decreased alphasynuclein expression in the aging mouse substantia nigra. Exp. Neurol., 2009, 220, 359.
16. Michell, A.W.; Tofaris, G.K.; Gossage, H.; Tyers, P; Spillantini, M.G.; Barker, R.A. The effect of truncated human alpha-synuclein (1-120) on dopaminergic cells in a transgenic mouse model of Parkinson's disease. Cell Transplant., 2007, 16, 461-474.
17. Schneider, B.L.; Seehus, C.R.; Capowski, E.E.; Aebischer, P.; Zhang, S.C.; Svendsen, C.N. Overexpression of alpha-synuclein in human neural progenitors leads to specific changes in fate and differentiation. Hum. Mol. Genet., 2007, 16, 651-666.
18. Costa, C.; Paitel, E.; Vincent, B. Alpha-synuclein lowers p53-dependent apoptotic response of neuronal cells. Abolishment by 6-hydroxydopamine and implication for Parkinson's disease. J. Biol. Chem., 2002, 277, 50980-50984.
19. Seo, J.H.; Rah, J.C.; Choi, S.H.; Shin, J.K.; Min, K.; Kim, H.S.; Park, C.H.; Kim, S.; Kim, E.M.; Lee, S.H.; Lee, S.; Suh, S.W.; Suh, Y.H. Alpha-synuclein regulates neuronal survival via Bcl-2 family expression and PI3/Akt kinase pathway. FASEB J., 2002, 16, 1826-1828.
20. Webb, J.L.; Ravikumar, B.; Atkins, J.; Skepper, J.N.; Rubinsztein, D.C. Alpha-Synuclein is degraded by both autophagy and the pro teasome. J. Biol. Chem., 2003, 278, 25009.
21. Bodles, A.M.; Guthrie, D.J.; Greer, B.; Irvine, G.B. Identification of the region of non-Abeta component (NAC) of Alzheimer's disease amyloid responsible for its aggregation and toxicity. J. Neurochem., 2001, 78, 384-395.
22. Halliday, G.M.; Del Tredici, K.; Braak, H. Critical appraisal of brain pathology staging related to presymptomatic and symptomatic cases of sporadic Parkinson's disease. J. Neural. Transm., 2006, 70, 99-103.
23. Conway, K.A.; Lee, S.J.; Rochet, J.C.; Ding, T.T.; Williamson, R.E.; Lansbury, P.T. Jr. Acceleration of oligomerization, not fibrillization, is a shared property of both α-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc. Natl. Acad. Sci., 2000, 97, 571.
24. Ren, J.P.; Zhao, Y.W.; Sun, X.J. Toxic influence of chronic oral administration of paraquat on nigrostriatal dopaminergic neurons in C57BL/6 mice. Chin. Med. J., 2009, 122, 2366.
25. Sherer, T.B.; Betarbet, R.; Stout, A.K.; Lund, S.; Baptista, M.; Panov, A.V.; Cookson, M.R.; Greenamyre, J.T. An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered α-synuclein metabolism and oxidative damage. J. Neurosci., 2002, 22, 7006.
26. Haggerty, T.; Credle, J.; Rodriguez, O.; Wills, J.; Oaks, A.W.; Masliah, E.; Sidhu, A. Hyperphosphorylated Tau in an α-synucleinoverexpressing transgenic model of Parkinson's disease. Eur. J. Neurosci., 2011, 33(9), 1598-1610.
27. Masliah, E.; Rockenstein, E.; Veinbergs, I. β-amyloid peptides enhance α-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc. Natl. Acad. Sci., 2001, 98, 12245.
28. Hashimoto, M.; Rockenstein, E.; Mante, M.; Mallory, M.; Masliah, E. β-synuclein inhibits α-synuclein aggregation: a possible role as an anti-parkinsonian factor. Neuron., 2001, 32, 213.
29. Li, J.Y.; Englund, E.; Holton, J.L.; Soulet, D.; Hagell, P.; Lees, A.J.; Lashley, T.; Quinn, N.P.; Rehncrona, S.; Björklund, A.; Widner, H.; Revesz, T.; Lindvall, O.; Brundin, P. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest hostto-graft disease propagation. Nat. Med., 2008, 14, 501.
30. Ostrerova-Golts, N.; Petrucelli, L.; Hardy, J.; Lee, J.M.; Farer, M.; Wolozin, B. The A53T alpha-synuclein mutation increases irondependent aggregation and toxicity. J. Neurosci., 2000, 20(16), 6048-54.
31. Krüger, R.; Kuhn, W.; Müller, T.; Woitalla, D.; Graeber, M.; Kösel, S.; Przuntek, H.; Epplen, J.T.; Schöls, L.; Riess, O. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet., 1998, 18, 106.
32. Lucking, C.B.; Briece, A. Alpha-synuclein and Parkinson's disease. Cell. Mol. Life. Sci., 2000, 57, 1894.
33. Narhi, L.; Wood, S.J.; Steavenson, S.; Jiang, Y.; Wu, G.M.; Anafi, D.; Kaufman, S.A.; Martin, F.; Sitney, K.; Denis, P.; Louis, J.C.; Wypych, J.; Biere, A.L.; Citron, M. Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation. J. Biol. Chem., 1999, 274, 9843.
34. Zarranz, J.J.; Alegre, J.; Gómez-Esteban, J.C.; Lezcano, E.; Ros, R.; Ampuero, I.; Vidal, L.; Hoenicka, J.; Rodriguez, O.; Atarés, B.; Llorens, V.; Gomez Tortosa, E.; del Ser, T.; Muñoz, D.G.; de Yebenes, J.G. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol., 2004, 55, 164.
35. Pandey, N.; Schmidt, R.E.; Galvin, J.E. The alpha-synuclein mutation E46K promotes aggregation in cultured cells. Exper. Neurol., 2006, 197, 515.
36. Nishioka, K.; Ross, O.A.; Ishii, K.; Kachergus, J.M.; Ishiwata, K.; Kitagawa, M.; Kono, S.; Obi, T.; Mizoguchi, K.; Inoue, Y.; Imai, H.; Takanashi, M.; Mizuno, Y.; Farrer, M.J.; Hattori, N. Expanding the clinical phenotype of SNCA duplication carriers. Mov. Disord., 2009, 24, 1811-1819.
37. Ito, S.; Nakaso, K.; Imamura, K.; Takeshima, T.; Nakashima, K. Endogenous catecholamine enhances the dysfunction of unfolded protein response and alpha-synuclein oligomerization in PC12 cells overexpressing human alpha-synuclein. Neurosci. Res., 2010, 66, 124.
38. Pham, C.L.; Leong, S.L.; Ali, F.E.; Kenche, V.B.; Hill, A.F.; Gras, S.L.; Barnham, K.J.; Cappai, R. Dopamine and the dopamine oxidation product 5,6-dihydroxylindole promote distinct on-pathway and off-pathway aggregation of alpha-synuclein in a pH-dependent manner. J. Mol. Biol., 2009, 387, 771.
39. Da Costa, C.A.; Ancolio, K.; Checler, F. Wild-type but not Parkinson's disease-related Ala53Thr mutant alpha-synuclein protects neuronal cells from apoptotic stimuli. J. Biol. Chem., 2000, 275, 24065.
40. Baptista, M.J.; O'Farrell, C.; Daya, S. Co-ordinate transcriptional regulation of dopamine synthesis genes by alpha-synuclein In human neuroblastoma cell lines. J. Neurochem., 2003, 85, 957.
41. Dai, J.G.; Murakami K. Constitutively and autonomously active protein kinase C associated with 14-3-3 zeta in the rodent brain. J. Neurochem., 2003, 84, 23.
42. Lee, D.; Lee, S.Y.; Lee, E.N.; Chang, C.S.; Paik, S.R. Alpha-Synuclein exhibits competitive interaction between calmodulin and synthetic membranes. J. Neurochem., 2002, 82, 1007.
43. Maguire-Zeiss, K.A.; Short, D.W.; Federoff, H.J. Synuclein, dopamine and oxidative stress: coconspirators in Parkinson. s disease? Mol. Brain Res., 2005, 134, 18.
44. Lotharius, J.; Barg, S.; Wiekop, P.; Lundberg, C.; Raymon, H.K.; Brundin, P. Effect of mutant α-synuclein on dopamine homeostasis in a new human mesencephalic cell line. J. Biol. Chem., 2002, 277, 38884.
45. Tan, E.K.; Tan, C.; Shen, H.; Chai, A.; Lum, S.Y.; Teoh, M.L.; Yih, Y.; Wong, M.C.; Zhao, Y. Alpha synuclein promoter and risk of Parkinson's disease: microsatellite and allelic size variability. Neurosci. Lett., 2003, 336, 70.
46. Eisenhofer, G.; Kopin, I.J.; Goldstein, D.S. Catecholamine metabolism: a contemporary view with implications for physiology and medicine. Pharmacol. Rev., 2004, 56, 331.
47. Januszewicz, W.; Wocial, B.; Sznajderman, M. Guz chromochłonny. Wydawnictwo Lekarskie PZWL, Warsaw, 2000, 18, 1019-1023.
48. Lotharius, J.; Brundin, P. Impaired dopamine storage resulting from alpha-synuclein mutations may contribute to the pathogenesis of Parkinson's disease. Hum. Mol. Genet., 2002, 11, 2395.
49. Półrolniczak A.; Dorszewska, J.; Białek, P.; Florczak-Wyspiańska, J.; Owecki, M.; Kozubski, W. Analysis of the frequency of mutations in genes important for molecular diagnostics of Parkinson disease. Acta Bioch. Pol., 2012, 59(3), 16.
50. Singleton, A.B.; Farrer, M.; Johnson, J.; Singleton, A.; Hague, S.; Kachergus, J.; Hulihan, M.; Peuralinna, T.; Dutra, A.; Nussbaum, R.; Lincoln, S.; Crawley, A.; Hanson, M.; Maraganore, D.; Adler, C.; Cookson, M.R.; Muenter, M.; Baptista, M.; Miller, D.; Blancato, J.; Hardy, J.; Gwinn-Hardy, K. Alpha-Synuclein locus triplication causes Parkinson's disease. Science, 2003, 302, 841.
51. Mutez, E.; Leprêtre, F.; Le Rhun, E.; Larvor, L.; Duflot, A.; Mouroux, V.; Kerckaert, J.P.; Figeac, M.; Dujardin, K.; Destée, A.; Chartier-Harlin, M.C. SNCA locus duplication carriers: from genetics to Parkinson disease phenotypes. Hum. Mutat., 2011, 32, 2079.
52. Goldstein, D.S.; Eisenhofer, G.; Kopin, I.J. Clinical catecholamine neurochemistry: a legacy of Julius Axelrod. Cell. Mol. Neurobiol., 2006, 26, 695.
53. Goldstein, D.S.; Holmes, C.; Li, S.T.; Bentho, O.; Saleem, A.; Pacak, K.; Eisenhofer, G. Cardiac sympathetic denervation in Parkinson disease. Ann. Intern. Med., 2000, 133, 338.
54. Sironi, F.; Trotta, L.; Antonini, A.; Zini, M.; Ciccone, R.; Della Mina, E.; Meucci, N.; Sacilotto, G.; Primignani, P.; Brambilla, T.; Coviello, D.A.; Pezzoli, G.; Goldwurm, S. Alpha-Synuclein multiplication analysis in Italian familial Parkinson disease. Parkinsonism. Relat. Disord., 2010, 16, 228.
55. Obi, T.; Nishioka, K.; Ross, O.A.; Terada, T.; Yamazaki, K.; Sugiura, A.; Takanashi, M.; Mizoguchi, K.; Mori, H.; Mizuno, Y.; Hattori, N. Clinicopathologic study of a SNCA gene duplication patient with Parkinson disease and dementia. Neurology, 2008, 70, 238.
56. Nishioka, K.; Wider, C.; Vilarino-Guell, C.; Soto-Ortolaza, A.I.; Lincoln, S.J.; Kachergus, J.M.; Jasinska-Myga, B.; Ross, O.A.; Rajput, A.; Robinson, C.A.; Ferman, T.J.; Wszolek, Z.K.; Dickson, D.W.; Farrer, M.J. Association of alpha-, beta-, and gamma-Synuclein with diffuse lewy body disease. Arch. Neur., 2010, 67, 970.
57. Chiba-Falek, O.; Lopez, G.J.; Nussbaum, R.L. Levels of alphasynuclein mRNA in sporadic Parkinson disease patients. Mov. Disord., 2006, 21, 1703.
58. Fuchs, J.; Tichopad, A.; Golub, Y.; Munz, M.; Schweitzer, K.J.; Wolf, B.; Berg, D.; Mueller, J.C.; Gasser, T. Genetic variability in the SNCA gene influences alpha-synuclein levels in the blood and brain. FASEB. J., 2008, 5, 1327.
59. Mellick, G.D.; Maraganore, D.M.; Silburn, P.A. Australian data and meta-analysis lend support for alpha-synuclein (NACP-Rep1) as a risk factor for Parkinson's disease. Neurosci. Lett., 2005, 375, 112.
60. Chiba-Falek, O.; Nussbaum, R.L. Effect of allelic variation at the NACP-Rep1 repeat upstream of the alpha-synuclein gene (SNCA) on transcription in a cell culture luciferase reporter system. Hum. Mol. Genet., 2001, 10, 3101.
61. Cronin, K.D.; Ge, D.; Manninger, P.; Linnertz, C.; Rossoshek, A.; Orrison, B.M.; Bernard, D.J.; El-Agnaf, O.M.; Schlossmacher, M.G.; Nussbaum, R.L.; Chiba-Falek, O. Expansion of the Parkinson disease-associated SNCA-Rep1 allele upregulates human alpha-synuclein in transgenic mouse brain. Hum. Mol. Genet., 2009, 18, 3274-3285.
62. Tan, E.K.; Matsuura, T.; Nagamitsu, S.; Khajavi, M.; Jankovic, J.; Ashizawa, T. Polymorphism of NACP-Rep1 in Parkinson's disease: an etiologic link with essential tremor? Neurology, 2000, 54, 1195-1198.
63. Maraganore, D.M.; de Andrade, M.; Elbaz, A. Genetic Epidemiology of Parkinson's Disease (GEO-PD) Consortium. Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease. JAMA., 2006, 296, 661-670.
64. Spadafora, P.; Annesi, G.; Pasqua, A.A.; Serra, P.; Cirò Candiano, I.C.; Carrideo, S.; Tarantino, P.; Civitelli, D.; De Marco, E.V.; Nicoletti, G.; Annesi, F.; Quattrone, A. NACP-REP1 polymorphism is not involved in Parkinson's disease: a case-control study in a population sample from southern Italy. Neurosci. Lett., 2003, 351, 75-78.
65. Ding, T.T.; Lee, S.J.; Rochet, J.C. Lansbury PT Jr. Annular asynuclein protofibrils are produced when spherical protofibrils are incubated in solution or bound to brain-derived membranes. Biochemistry, 2002, 41, 10209-10217.
66. Kahle, P.J.; Neumann, M.; Ozmen, L.; Muller, V.; Jacobsen, H.; Schindzielorz, A.; Okochi, M.; Leimer, U.; van Der Putten, H.; Probst, A.; Kremmer, E.; Kretzschmar, H.A.; Haass, C. Subcellular localization of wild-type and Parkinson's disease-associated mutant α-synuclein in human and transgenic mouse brain. J. Neurosci., 2000, 20, 6365.
67. Trotta, L.; Guella, I.; Soldà, G.; Sironi, F.; Tesei, S.; Canesi, M.; Pezzoli, G.; Goldwurm, S.; Duga, S.; Asselta, R. SNCA and MAPT genes: Independent and joint effects in Parkinson disease in the Italian population. Parkinsonism Relat. Disord., 2012, 18, 257-262.
68. Myhre, R.; Toft, M.; Kachergus, J.; Hulihan, M.M.; Aasly, J.O.; Klungland, H.; Farrer, M.J. Multiple alpha-synuclein gene polymorphisms are associated with Parkinson's disease in a Norwegian population. Acta. Neurol. Scand., 2008, 118, 320-327.
69. Kay, D.M.; Factor, S.A.; Samii, A.; Higgins, D.S.; Griffith, A.; Roberts, J.W.; Leis, B.C.; Nutt, J.G.; Montimurro, J.S.; Keefe, R.G.; Atkins, A.J.; Yearout, D.; Zabetian, C.P.; Payami, H. Genetic association between alpha-synuclein and idiopathic Parkinson's disease. Am. J. Med. Genet. B Neuropsychiatr. Genet., 2008, 147 B, 1222-1230.
70. Ritz, B.; Rhodes, S.L.; Bordelon, Y.; Broinstein, J. α-Synuclein Genetic Variants Predict Faster Motor Symptom Progression in Idiopathic Parkinson Disease. PLoS One, 2012, 7, 36199.
71. Hadjigeorgiou, G.M.; Xiromerisiou, G.; Gourbali, V. Association of alpha-synuclein Rep1 polymorphism and Parkinson's disease: influence of Rep1 on age at onset. Mov. Disord., 2006, 21, 534-539.
72. De Marco, E.V.; Tarantino, P.; Rocca, F.E. Alpha-synuclein promoter haplotypes and dementia in Parkinson's disease. Am. J. Med. Genet. B Neuropsychiatr. Genet., 2008, 147, 403-407.
73. Mata, I.F.; Lockhart, P.J.; Farrer, M.J. Parkin genetics: one model for Parkinson's disease. Hum. Mol. Genet., 2004, 13, 127.
74. Horowitz, J.M.; Myers, J.; Stachowiak, M.K.; Torres, G. Identification and distribution of parkin in rat brain. NeuroReport., 1996, 10, 3393-3397.
75. Bae, Y.J.; Park, K.S.; Kang, S.J. Genomic organization and expression of parkin in Drosophila melanogaster. Exp. Mol. Med., 2003, 35, 393-402.
76. Culetto, E.; Sattelle, D.B. A role for Caenorhabditis elegans in understanding the function and interactions of human disease genes. Hum. Mol. Genet., 2000, 9, 869-877.
77. Kitada, T.; Asakawa, S.; Hattori, N.; Matsumine, H.; Yamamura, Y.; Minoshima, S. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature, 1998, 392, 605-608.
78. Witte, M.E.; Bol, J.G.; Gerritsen, W.H.; van der Valk, P.; Drukarch, B.; van Horssen, J. Parkinson's disease-associated parkin colocalizes with Alzheimer's disease and multiple sclerosis brain lesions. Neurobiol. Dis., 2009, 36, 445-452.
79. Shimura, H.; Hattori, N.; Kubo, S.; Yoshikawa, M.; Kitada, T.; Matsumine, H.; Asakawa, S.; Minoshima, S.; Yamamura, Y.; Shimizu, N.; Mizuno, Y. Immunohistochemical and subcellular localization of parkin protein: absence of protein in autosomal recessive juvenile parkinsonism patients. Ann. Neurol., 1999, 45, 668-672.
80. Darios, F.; Corti, O.; Lücking, C.B.; Hampe, C.; Muriel, M.P.; Abbas, N.; Gu, W.J.; Hirsch, E.C.; Rooney, T.; Ruberg, M.; Brice, A. Parkin prevents mitochondrial swelling and cytochrome c release in mitochondria-dependent cell death. Hum. Mol. Genet., 2003, 12, 517-526.
81. Balsera, M.; Soll, J.; Bolter, B., Protein import machineries in endosymbiotic organelles. Cell. Mol. Life Sci., 2009, 66, 1903-1923.
82. Glinn, M.A.; Lee, C.P.; Ernster, L. Pro-and anti-oxidant activities of the mitochondrial respiratory chain:factors influencing NAD(P)H-induced lipid peroxidation. Biochimica. Et. Biophysica. Acta, 1997, 1318, 246-254.
83. Kuroda, Y.; Mitsui, T.; Kunishige, M.; Shono, M.; Akaike, M.; Azuma, H.; Matsumoto, T. Parkin enhances mitochondrial biogenesis in proliferating cells. Hum. Mol. Genet., 2006, 15, 883-895.
84. Zhang, Y.; Gao, J.; Chung, K.K.; Huang, H.; Dawson, V.L.; Dawson, T.M. Parkin functions as an E2-dependent ubiquitinprotein ligase and promotes the degradation of the synaptic vesicleassociated protein, CDCrel-1. Proc. Natl. Acad. Sci., 2000, 97, 13354.
85. Rothfuss, O.; Fischer, H.; Hasegawa, T.; Maisel, M.; Leitner, P.; Miesel, F.; Sharma, M.; Bornemann, A.; Berg, D.; Gasser, T.; Patenge, N. Parkin protects mitochondrial genome integrity and supports mitochondrial DNA repair. Hum. Mol. Genet., 2009, 18, 3832-3850.
86. Watson, R.E.; McKim, J.M.; Cockerell, G.L.; Goodman, J.I. The value of DNA methylation analysis in basic, initial toxicity assessments. Toxicol. Sci., 2004, 79, 178-188.
87. Temme, C.; Weissbach, R.; Lilie, H.; Wilson, C.; Meinhart, A.; Meyer, S.; Golbik, R.; Schierhorn, A.; Wahle, E. The Drosophila melanogaster gene cg4930 encodes a high affinity inhibitor for endonuclease G. J. Biol. Chem., 2009, 284, 8337-8348.
88. Batenburg, J.J.; Olson, M.S. Regulation of pyruvate dehydrogenase by fatty acid in isolated rat liver mitochondria. J. Biol. Chem., 1976, 251, 1364-1370.
89. Meisner, H. Energy-dependent uptake of ochratoxin A by mitochondria. Arch Biochem. Biophys., 1976, 173, 132-140.
90. Raikhinshtein, M.V.; Melik-Sarkisian, S.S.; Zaigraeva, G.G.; Kretovich, V.L. Inhibitory analysis of the respiration of bacteroids from the nodules of yellow lupine. Mikrobiologiia, 1976, 45, 210-216.
91. Sandri, G.; Panfili, E.; Sottocasa, G.L. The calcium-binding glycoprotein and mitochondrial calcium movements. Biochem. Biophys. Res. Commun., 1976, 68, 1272-1279.
92. Castilho, R.F.; Hansson, O.; Ward, M.W.; Budd, S.L.; Nicholls, D.G. Mitochondrial control of acute glutamate excitotoxicity in cultured cerebellar granule cells. J. Neurosci., 1998, 18, 10277-10286.
93. Chudapongse, P. Further studies on the effect of phosphoenolpyruvate on respiration-dependent calcium transport by rat heart mitochondria. Biochimica. Et. Biophysica. Acta, 1976, 423, 196-202.
94. Palacino, J.J.; Sagi, D.; Goldberg, M.S.; Krauss, S.; Motz, C.; Wacker, M.; Klose, J.; Shen, J. Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J. Biol. Chem., 2004, 279, 18614-18622.
95. Jiang, H.; Ren, Y.; Zhao, J.; Feng, J. Parkin protects human dopaminergic neuroblastoma cells against dopamine-induced apoptosis. Hum. Mol. Genet., 13, 1745-1754.
96. Shin, J.H.; Ko, H.S.; Kang, H.; Lee, Y.; Lee, Y.I.; Pletinkova, O.; Troconso, J.C.; Dawson, V.L.; Dawson, T.M. PARIS (ZNF746) repression of PGC-1alpha contributes to neurodegeneration in Parkinson's disease. Cell, 2011, 144, 689-702.
97. Narendra, D.; Tanaka, A.; Suen, D.F.; Youle, R.J. Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. J. Cell., 2008, 183, 795-803.
98. Glauser, L.; Sonnay, S.; Stafa, K.; Moore, D.J. Parkin promotes the ubiquitination and degradation of the mitochondrial fusion factor mitofusin 1. J. Neurochem., 2011, 118(4), 636-645.
99. Yoshii, S.R.; Kishi, C.; Ishihara, N.; Mizushima, N. Parkin mediates proteasome-dependent protein degradation and rupture of the outer mitochondrial membrane. J. Biol. Chem., 2011, 286(22), 19630-19640.
100. Chung, K.K.; Thomas, B.; Li, X.; Troncoso, J.C.; Marsh, L.; Dawson, V.L.; Dawson, T.M. S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function. Science, 2004, 304, 1328.
101. Shimura, H.; Schlossmacher, M.G.; Hattori, N.; Frosch, M.P.; Trockenbacher, A.; Schneider, R.; Mizuno, Y.; Kosik, K.S.; Selkoe, D.J. Ubiquitination of a new form of α-synuclein by parkin from human brain: implications for Parkinson's disease. Science, 2001, 293, 263.
102. Haass, C.; Kahle, P.J. Neuroscience. Parkin and its substrates. Science, 2001, 293, 224.
103. Okatsu, K.; Iemura, S.; Koyano, F.; Go, E.; Kimura, M.; Natsume, T.; Tanaka, K.; Matsuda, N. Mitochondrial hexokinase HKI is a novel substrate of the Parkin ubiquitin ligase. Biochem. Biophys. Res. Commun., 2012, 428(1), 197-202.
104. Matsuda, N.; Kitami, T.; Suzuki, T.; Mizuno, Y.; Hattori, N.; Tanaka, K. Diverse effects of pathogenic mutations of parkin that catalyze multiple monoubiquitylation in vitro. J. Biol. Chem., 2006, 281, 3204-3209.
105. Hampe, C.; Ardila-Osorio, H.; Fournier, M.; Brice, A.; Corti, O. Biochemical analysis of Parkinson's disease-causing variants of Parkin, an E3 ubiquitin-protein ligase with monoubiquitylation capacity. Hum. Mol. Genet., 2006, 15, 2059-2075.
106. Doss-Pepe, E.W.; Chen, L.; Madura, K. Alpha-synuclein and parkin contribute to the assembly of ubiquitin lysine 63-linked multiubiquitin chains. J. Biol. Chem., 2005, 280, 16619-16624.
107. Mukhopadhyay, D.; Riezman, H. Proteasome-independent functions of ubiquitin in endocytosis and signaling. Science, 2007, 315, 201-205.
108. Henn, I. H.; Bouman, L.; Schlehe, J. S.; Schlierf, A.; Schramm, J.E.; Wegener, E.; Nakaso, K.; Culmsee, C.; Berninger, B.; Krappmann, D.; Tatzelt, J.; Winklhofer, K.F. Parkin mediates neuroprotection through activation of IkappaB kinase/nuclear factorkappaB signaling. J. Neurosci., 2007, 27, 1868.
109. Lim, K. L.; Dawson, V.L.; Dawson, T.M. Parkin-mediated lysine 63-linked polyubiquitination: a link to protein inclusions formation in Parkinson's and other conformational diseases? Neurobiol. Aging, 2006, 27, 524.
110. Kopito, R.R. Aggresomes, inclusion bodies and protein aggregation. Trends Cell Biol., 2000, 10, 524.
111. Oyama, G.; Yoshimi, K.; Natori, S.; Chikaoka, Y.; Ren, Y.R.; Funayama, M.; Shimo, Y.; Takahashi, R.; Nakazato, T.; Kitazawa, S.; Hattori, N. Impaired in vivo dopamine release in parkin knockout mice. Brain Res., 2010, 17, 1352.
112. Marazziti, D.; Mandillo, S.; Di Pietro, C.; Golini, E.; Matteoni, R.; Tocchini-Valentini, G.P. GPR37 associates with the dopamine transporter to modulate dopamine uptake and behavioral responses to dopaminergic drugs. Proc. Natl. Acad. Sci., 2007, 104, 9846.
113. Hasegawa, T.; Treis, A.; Patenge, N.; Fiesel, F.C.; Springer, W.; Kahle, P.J. Parkin protects against tyrosinase-mediated dopamine neurotoxicity by suppressing stress-activated protein kinase pathways. J. Neurochem., 2008, 105, 1700.
114. LaVoie, M.J., Cortese, G.P.; Ostaszewski, B.L.; Schlossmacher, M.G. The effects of oxidative stress on parkin and other E3 ligases. J. Neurochem., 2007, 103, 2354.
115. Wong, E.S.; Tan, J.M.; Wang, C.; Zhang, Z.; Tay, S.P.; Zaiden, N.; Ko, H.S.; Dawson, V.L.; Dawson, T.M.; Lim, K.L. Relative sensitivity of parkin and other cysteine-containing enzymes to stressinduced solubility alterations. J. Biol. Chem., 2007, 282, 12310.
116. Shimura, H.; Hattori, N.; Kubo, S.; Mizuno, Y.; Asakawa, S.; Minoshima, S.; Shimizu, N.; Iwai, K.; Chiba, T.; Tanaka, K.; Suzuki, T. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat. Genet., 2000, 25, 302-305.
117. West, A.B.; Zimprich, A.; Lockhart, P.J.; Farrer, M.; Singleton, A.; Holtom, B.; Lincoln, S.; Hofer, A.; Hill, L.; Müller-Myhsok, B.; Wszolek, Z.K.; Hardy, J.; Gasser, T. Refinement of the PARK3 locus on chromosome 2p13 and the analysis of 14 candidate genes. Eur. J. Hum. Genet., 2001, 9, 659-666.
118. West, A.B.; Maraganore, D.; Crook, J.; Lesnick, T.; Lockhart, P.J.; Wilkes, K.M.; Kapatos, G.; Hardy, J.A.; Farrer, M.J. Functional association of the parkin gene promoter with idiopathic Parkinson's disease. Hum. Mol. Genet., 2002, 11, 2787.
119. Matsumine, H.; Saito, M.; Shimoda-Matsubayashi, S.; Tanaka, H.; Ishikawa, A.; Nakagawa-Hattori, Y.; Yokochi, M.; Kobayashi, T.; Igarashi, S.; Takano, H.; Sanpei, K.; Koike, R.; Mori, H.; Kondo, T.; Mizutani, Y.; Schäffer, A.A.; Yamamura, Y.; Nakamura, S.; Kuzuhara, S.; Tsuji, S.; Mizuno, Y. Localization of a gene for an autosomal recessive form of juvenile Parkinsonism to chromosome 6q25.2-27. Am. J. Hum. Genet., 1997, 60, 588-596.
120. Półrolniczak, A.; Dorszewska, J.; Florczak, J.; Owecki, M.; Różycka, A.; Rubiś, B.; Marcinkowski, M.; Osmola, K.; Krahel, A.; Lewandowski, L.; Jagodziski, P.; Kozubski, W. Analysis of PARK2 gene mutation in sporadic Parkinson's disease. Folia. Neuropathol, 2010, 48, 314.
121. Wang, H.; Song, P.; Du, L. Parkin ubiquitinates Drp1 for proteasome-dependent degradation: implication of dysregulated mitochondrial dynamics in Parkinson's disease. J. Biol. Chem., 2011, 286, 11649-11658.
122. Foroud, T.; Uniacke, S.K.; Liu, L.; Pankratz, N.; Rudolph, A.; Halter, C.; Shults, C.; Marder, K.; Conneally, P.M.; Nichols, W.C.; Parkinson Study Group Heterozygosity for a mutation in the parkin gene leads to later onset Parkinson disease. Neurology, 2003, 60, 796-801.
123. Półrolniczak, A.; Dorszewska, J.; Florczak, J.; Owecki, M.; Różycka, A.; Rubiś, B.; Jagodziski, P.; Kozubski, W. Analysis of SNCA and PARK2 mutations in sporadic parkinson's disease. Neurodegener. Dis., 2011, s1, 11.
124. Hedrich, K.; Eskelson, C.; Wilmot, B.; Marder, K.; Harris, J.; Garrels, J.; Meija-Santana, H.; Vieregge, P.; Jacobs, H.; Bressman, S.B.; Lang, A.E.; Kann, M.; Abbruzzese, G.; Martinelli, P.; Schwinger, E.; Ozelius, L.J.; Pramstaller, P.P.; Klein, C.; Kramer, P. Distribution, type, and origin of Parkin mutations: review and case studies. Mov. Disord., 2004, 19, 1146-1157.
125. Kann, M.; Jacobs, H.; Mohrmann, K. Role of parkin mutations in 111 community-based patients with early-onset parkinsonism. Ann. Neurol., 2002, 51, 621-625.
126. Choi, J.M.; Woo, M.S.; Ma, H.I.; Kang, S.Y.; Sung, Y.H.; Yong, S.W.; Chung, S.J.; Kim, J.S.; Shin, H.W.; Lyoo, C.H.; Lee, P.H.; Baik, J.S.; Kim, S.J.; Park, M.Y.; Sohn, Y.H.; Kim, J.H.; Kim, J.W.; Lee, M.S.; Lee, M.C.; Kim, D.H.; Kim, Y.J. Analysis of PARK genes in a Korean cohort of early-onset Parkinson disease. Neurogenetics, 2008, 9, 263-269.
127. Sironi, F.; Primignani, P.; Zini, M.; Tunesi, S.; Ruffmann, C.; Ricca, S.; Brambilla, T.; Antonini, A.; Tesei, S.; Canesi, M.; Zecchinelli, A.; Mariani, C.; Meucci, N.; Sacilotto, G.; Cilia, R.; Isaias, I.U.; Garavaglia, B.; Ghezzi, D.; Travi, M.; Decarli, A.; Coviello, D.A.; Pezzoli, G.; Goldwurm, S. Parkin analysis in early onset Parkinson's disease. Parkinsonism Relat. Disord., 2008, 14, 326-333.
128. Mellick, G.D.; Siebert, G.A.; Funayama, M.; Buchanan, D.D.; Li, Y.; Imamichi, Y.; Yoshino, H.; Silburn, P.A.; Hattori, N. Screening PARK genes for mutations in early-onset Parkinson's disease patients from Queensland, Australia. Parkinsonism Relat. Disord., 2009, 15, 105-109.
129. Abbas, N.; Lucking, C.B.; Ricard, S.; Dürr, A.; Bonifati, V.; De Michele, G.; Bouley, S.; Vaughan, J.R.; Gasser, T.; Marconi, R.; Broussolle, E.; Brefel-Courbon, C.; Harhangi, B.S.; Oostra, B.A.; Fabrizio, E.; Böhme, G.A.; Pradier, L.; Wood, N.W.; Filla, A.; Meco, G.; Denefle, P.; Agid, Y.; Brice, A. A wide variety of mutations in the parkin gene are responsible for autosomal recessive parkinsonism in Europe. Hum. Mol. Genet., 1999, 8, 567-574.
130. Periquet, M.; Latouche, M.; Lohmann, E.; Rawal, N.; De, M.G.; Ricard, S.; Teive, H.; Fraix, V.; Vidailhet, M.; Nicholl, D.; Barone, P.; Wood, N.W.; Raskin, S.; Deleuze, J.F.; Agid, Y.; Durr, A.; Brice, A. Parkin mutations are frequent in patients with isolated early-onset parkinsonism. Brain, 2003, 126, 1271-1278.
131. Oliveira, S.A.; Scott, W.K.; Martin, E.R.; Nance, M.A.; Watts, R.L.; Hubble, J.P.; Koller, W.C.; Pahwa, R. Parkin mutations and susceptibility alleles in late-onset Parkinson's disease. Ann. Neurol., 2003, 53, 624-629.
132. Klein, C.; Djarmati, A.; Hedrich, K.; Schafer, N.; Scaglione, C.; Marchese, R.; Kock, N.; Schule, B.; Hiller, A.; Lohnau, T.; Winkler, S.; Wiegers, K.; Hering, R.; Bauer, P.; Riess, O.; Abbruzzese, G.; Martinelli, P.; Pramstaller, P.P. PINK1, Parkin, and DJ-1 mutations in Italian patients with early-onset parkinsonism. Eur. J. Hum. Genet., 2005, 13, 1086-1093.
133. Chen, R.; Gosavi, N.S.; Langston, J.W.; Chan, P. Parkin mutations are rare in patients with young-onset parkinsonism in a US population. Parkinsonism Relat. Disord., 2003, 9, 309-312.
134. Periquet, M.; Lucking, C.B.; Vaughan, J.R.; Chan, P. Origin of mutations in the parkin gene in Europe: exon rearrangements are independent recurrent events, whereas point mutations may result from founder effects. Am. J. Hum. Genet., 2001, 68, 617-626.
135. Leroy, E.; Anastasopoulos, D.; Konitsiotis, S.; Lavedan, C.; Polymeropoulos, M.H. Deletions in the Parkin gene and genetic heterogeneity in a Greek family with early onset Parkinson's disease. Hum. Genet., 1998, 103, 424-427.
136. Hedrich, K.; Kann, M.; Lanthaler, A.J.; Dalski, A.; Eskelson, C.; Landt, O.; Schwinger, E.; Vieregge, P.; Lang, A.E.; Breakefield, X.O.; Ozelius, L.J.; Pramstaller, P.P.; Klein, C. The importance of gene dosage studies: mutational analysis of the parkin gene in early-onset parkinsonism. Hum. Mol. Genet., 2001, 10, 1649-1656.
137. Lucking, C.B.; Abbas, N.; Durr, A.; Bonifati, V.; Bonnet, A.M.; De, M.G.; Wood, N.W.; Agid, Y.; Brice, A. Homozygous deletions in parkin gene in European and North African families with autosomal recessive juvenile parkinsonism. The European Consortium on Genetic Susceptibility in Parkinson's Disease and the French Parkinson's Disease Genetics Study Group. Lancet, 1998, 352, 1355-1356.
138. Maruyama, M.; Ikeuchi, T.; Saito, M.; Ishikawa, A.; Yuasa, T.; Tanaka, H.; Hayashi, S.; Wakabayashi, K.; Takahashi, H.; Tsuji, S. Novel mutations, pseudo-dominant inheritance, and possible familial affects in patients with autosomal recessive juvenile parkinsonism. Ann. Neurol., 2000, 48, 245-250.
139. Lücking, C.B.; Bonifati, V.; Periquet, M.; Vanacore, N.; Brice, A.; Meco, G. Pseudo-dominant inheritance and exon 2 triplication in a family with parkin gene mutations. Neurology, 2001, 57(5), 924-927.
140. Elfferich, P.; Verleun-Mooijman, M.C.;Maat-Kievit, J.A.; van de Warrenburg, B.P.; Abdo, W.F.; Eshuis, S.A.; Leenders, K.L.; Hovestadt, A.; Zijlmans, J.C.; story, J.P.; van Swieten, J.C.; Boon, A.J.; van Engelen, K.; Verschuuren-Bemelmans, C.C.; Lesnik-Oberstein, S.A.; Tassorelli, C.; Lopiano, L.; Bonifati, V.; Dooijes, D.; van Minkelen, R. Breakpoint mapping of 13 large parkin deletions/ duplications reveals an exon 4 deletion and an exon 7 duplication as founder mutations. Neurogenetics., 2011, 12(4), 263-271.
141. Nuytemans, K.; Theuns, J.; Cruts, M.; Van Broeckhoven, C.; Genetic Etiology of Parkinson Disease Associated with Mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 Genes: A Mutation Update. Hum. Mutat., 2010, 31, 763-780.
142. Smith, D.I.; Zhu, Y.; McAvoy, S.; Kuhn, R.; Common fragile sites, extremely large genes, neural development and cancer. Cancer Lett., 2006, 232(1), 48-57.
143. Denison, S.R.; Callahan, G.; Becker, N.A.; Phillips, L.A.; Smith, D.I. Characterization of FRA6E and its potential role in autosomal recessive juvenile parkinsonism and ovarian cancer. Genes Chromosomes Cancer, 2003, 38(1), 40-52.
144. Hedrich, K.; Djarmati, A.; Schäfer, N.; Hering, R.; Wellenbrock, C.; Weiss, P.H.; Hilker, R.; Vieregge, P.; Ozelius, L.J.; Heutink, P.; Bonifati, V.; Schwinger, E.; Lang, A.E.; Noth, J.; Bressman, S.B.; Pramstaller, P.P.; Riess, O.; Klein, C. DJ-1 (PARK7) mutations are less frequent than Parkin (PARK2) mutations in early-onset Parkinson disease. Neurology., 2004, 62(3), 389-394.
145. Guo, J.F.; Zhang, X.W.; Nie, L.L.; Zhang, H.N.; Liao, B.; Li, J.; Wang, L.; Yan, X.X.; Tang, B.S. Mutation analysis of Parkin, PINK1 and DJ-1 genes in Chinese patients with sporadic early onset parkinsonism. J. Neurol., 2010, 257, 1170-1175.
146. Pankratz, N.; Kissell, D.K.; Pauciulo, M.W.; Halter, C.A.; Rudolph, A.; Pfeiffer, R.F.; Marder, K.S.; Foroud, T.; Nichols, W.C., Parkinson Study Group-PROGENI Investigators. Parkinson Study Group-PROGENI Investigators Parkin dosage mutations have greater pathogenicity in familial PD than simple sequence mutations. Neurology, 2009, 73, 279-286.
147. Macedo, M.G.; Verbaan, D.; Fang, Y.; van Rooden, S.M.; Visser, M.; Anar, B.; Uras, A.; Groen, J.L.; Rizzu, P.; van Hilten, J.J.; Heutink, P. Genotypic and phenotypic characteristics of Dutch patients with early onset Parkinson's disease. Mov. Disord., 2009, 24, 196-203.
148. Schapira, A.H.; Dopamine agonists and neuroprotection in Parkinson's disease. Eur. J. Neurol., 2002, s3, 7-14.
149. Cookson, M.R.; Hardy, J.; Lewis, P.A. Genetic Neuropathology of Parkinson's Disease. Int. J. Clin. Exp. Patho., 2008, 1, 217-231.
150. Krüger, R.; Vieira-Säcker, A.M.; Kuhn, W.; Müller, T.; Woitalla, D.; Schöls, L.; Przuntek, H.; Epplen, J.T.; Riess, O. Analysis of the parkin deletion in sporadic and familial Parkinson's disease. J. Neural. Transm., 1999, 106(2), 159-163.
151. Sinha, R.; Racetteb, B.; Perlmutterb, J.S.; Parsian, A. Prevalence of parkin gene mutations and variations in idiopathic Parkinson's disease. Parkinsonism Relat. Disord., 2005, 11, 341-347.
152. Barsottini, O.G.; Felício, A.C.; de Carvalho Aguiar, P.; Godeiro Junior, C.; Pedroso, J.L.; de Aquino, C.C.; Bor-Seng-Shu, E.; de Andrade, L.A. Heterozygous exon 3 deletion in the Parkin gene in a patient with clinical and radiological MSA-C phenotype. Clin. Neurol. Neurosurg., 2011, 113(5), 404-406.
153. Oliveri, R.L.; Zappia, M.; Annesi, G.; Bosco, D.; Annesi, F.; Spadafora, P.; Pasqua, A.A.; Tomaino, C.; Nicoletti, G.; Pirritano, D.; Labate, A.; Gambardella, A.; Logroscino, G.; Manobianca, G.; Epifanio, A.; Morgante, L.; Savettieri, G.; Quattrone, A. The parkin gene is not involved in late-onset Parkinson's disease. Neurology, 2001, 57, 359-362.
154. Wang, T.; Liang, Z.; Sun, S.; Cao, X.; Peng, H.; Liu, H.; Tong, E. Exon deletions of parkin gene in patients with Parkinson disease. J. Huazhong. Univ. Sci. Technolog. Med. Sci., 2004, 24(3), 262-265.
155. Bonifati, V.; De Michele, G.; Lücking, C.B.; Dürr, A.; Fabrizio, E.; Ambrosio, G.; Vanacore, N.; De Mari, M.; Marconi, R.; Capus, L.; Breteler, M.M.; Gasser, T.; Oostra, B.; Wood, N.; Agid, Y.; Filla, A.; Meco, G.; Brice, A.; Italian PD Genetics Study Group; French PD Genetics Study Group; European Consortium on Genetic Susceptibility in PD. The parkin gene and its phenotype. Italian PD Genetics Study Group, French PD Genetics Study Group and the European Consortium on Genetic Susceptibility in Parkinson's Disease. Neurol. Sci., 2001, 22(1), 51-52.
156. Clarimon, J.; Johnson, J.; Dogu, O.; Horta, W.; Khan, N.; Lees, A.J.; Hardy, J.; Singleton, A. Defining the ends of Parkin exon 4 deletions in two different families with Parkinson's disease. Am. J. Med. Genet.B. Neuropsychiatr. Genet., 2005, 133(1), 120-123.
157. Nakaso, K.; Adachi, Y.; Yasui, K.; Sakuma, K.; Nakashima, K. Detection of compound heterozygous deletions in the parkin gene of fibroblasts in patients with autosomal recessive hereditary parkinsonism (PARK2). Neurosci. Lett., 2006, 400(1-2), 44-47.
158. Bayrakli, F.; Bilguvar, K.; Mason, C.E.; DiLuna, M.L.; Bayri, Y.; Gungor, L.; Terzi, M.; Mane, S.M.; Lifton, R.P.; State, M.W.; Gunel, M. Rapid identification of disease-causing mutations using copy number analysis within linkage intervals. Hum. Mutat., 2007, 28(12), 1236-1240.
159. Veeriah, S.; Morris, L.; Solit, D.; Chan, T.A. The familial Parkinson disease gene PARK2 is a multisite tumor suppressor on chromosome 6q25.2-27 that regulates cyclin E. Cell. Cycle., 2010, 9(8), 1451-1452.
160. Hu, C.J.; Sung, S.M.; Liu, H.C.; Lee, C.C.; Tsai, C.H.; Chang, J.G. Polymorphisms of the parkin gene in sporadic Parkinson's disease among Chinese in Taiwan. Eur. Neurol., 2000, 44(2), 90-93.
161. Satoh, J.; Kuroda, Y. Association of codon 167 Ser/Asn heterozygosity in the parkin gene with sporadic Parkinson's disease. NeuroReport., 1999, 10(13), 2735-2739.
162. Wang, M.; Hattori, N.; Matsumine, H.; Kobayashi, T.; Yoshino, H.; Morioka, A.; Kitada, T.; Asakawa, S.; Minoshima, S.; Shimizu, N.; Mizuno, Y. Polymorphism in the parkin gene in sporadic Parkinson's disease. Ann. Neurol., 1999, 45(5), 655-658.
163. Klein, C.; Schumacher, K.; Jacobs, H.; Hagenah, J.; Kis, B.; Garrels, J.; Schwinger, E.; Ozelius, L.; Pramstaller, P.; Vieregge, P.; Kramer, P.L. Association studies of Parkinson's disease and parkin polymorphisms. Ann. Neurol., 2000, 48(1), 126-127.
164. Farrer, M.; Chan, P.; Chen, R.; Tan, L.; Lincoln, S.; Hernandez, D.; Forno, L.; Gwinn-Hardy, K.; Petrucelli, L.; Hussey, J.; Singleton, A.; Tanner, C.; Hardy, J.; Langston, J.W. Lewy bodies and parkinsonism in families with parkin mutations. Ann. Neurol, 2001, 50, 293.
165. Hedrich, K.; Marder, K.; Harris, J.; Kann, M.; Lynch, T.; Meija-Santana, H.; Pramstaller, P.P.; Schwinger, E.; Bressman, S.B.; Fahn, S.; Klein, C. Evaluation of 50 probands with early-onset Parkinson's disease for Parkin mutations. Neurology., 2002, 58(8), 1239-1246.
166. Scott, W.K.; Nance, M.A.; Watts, R.L.; Hubble, J.P.; Koller, W.C.; Lyons, K.; Pahwa, R.; Stern, M.B.; Colcher, A.; Hiner, B.C.; Jankovic, J.; Ondo, W.G.; Allen, F.H. Jr.; Goetz, C.G.; Small, G.W.; Masterman, D.; Mastaglia, F.; Laing, N.G.; Stajich, J.M.; Slotterbeck, B.; Booze, M.W.; Ribble, R.C.; Rampersaud, E.; West, S.G.; Gibson, R.A.; Middleton, L.T.; Roses, A.D.; Haines, J.L.; Scott, B.L.; Vance, J.M.; Pericak-Vance, M.A. Complete genomic screen in Parkinson disease: evidence for multiple genes. JAMA., 2001, 286(18), 2239-2244.
167. Håkansson, A.; Carmine Belin, A.; Stiller, C.; Sydow, O.; Johnels, B.; Olson, L.; Holmberg, B.; Nissbrandt, H. Investigation of genes related to familial forms of Parkinson's disease-With focus on the Parkin gene. Parkinsonism Relat. Disord., 2008, 14, 520-522.
168. Kann, M.; Jacobs, H.; Mohrmann, K.; Schumacher, K.; Hedrich, K.; Garrels, J.; Wiegers, K.; Schwinger, E.; Pramstaller, P.P.; Breakefield, X.O.; Ozelius, L.J.; Vieregge, P.; Klein, C. Role of parkin mutations in 111 community-based patients with earlyonset parkinsonism. Ann. Neurol., 2002, 51, 621-625.
169. Dawson, T.M.; Dawson, V.L. Molecular pathways of neurodegeneration in Parkinson's disease. Science, 2003, 302, 819-822.
170. Khan, N.L.; Scherfler, C.; Graham, E. Dopaminergic dysfunction in unrelated.; asymptomatic carriers of a single parkin mutation. Neurology, 2005, 64, 134-136.
171. Buhmann, C.; Binkofski, F.; Klein, C.; Büchel, C.; van Eimeren, T.; Erdmann, C.; Hedrich, K.; Kasten, M.; Hagenah, J.; Deuschl, G.; Pramstaller, P.P.; Siebner, H.R. Motor reorganization in asymptomatic carriers of a single mutant Parkin allele: a human model for presymptomatic parkinsonism. Brain, 2005, 128, 2281-2290.
172. Walter, U.; Klein, C.; Hilker, R.; Benecke, R.; Pramstaller, PP.; Dressler, D. Brain parenchyma sonography detects preclinical parkinsonism. Mov. Disord., 2004, 19(12), 1445-1449.
173. Giasson, B.I.; Lee, V.M. Parkin and the molecular pathways of Parkinson's disease. Neuron, 2001, 31(6), 885-888.
174. Kahle, P.J.; Leimer, U.; Haass, C. Does failure of parkin-mediated ubiquitination cause juvenile parkinsonism? Trends Biochem. Sci., 2000, 25(11), 524-527.
175. Martínez, H.R.; González-González, H.; Cantú-Martínez, L.; Rangel-Guerra, R.; Hernández-Castillo, C.D.; Vergara-Saavedra, J.J.; Ramos-Gonzalez, M.R.; Cerda-Flores, R.M.; Morales-Garza, M.A.; Guerrero-Muñoz, M.J.; Montes-de-Oca-Luna, R.; Saucedo-Cárdenas, O. PARKIN-coding polymorphisms are not associated with Parkinson's disease in a population from northeastern Mexico. Neurosci. Lett., 2010, 468(3), 264-266.
176. Koziorowski, D.; Hoffman-Zacharska, D.; Sławek, J.; Szirkowiec, W.; Janik, P.; Bal, J.; Friedman, A. Low frequency of the PARK2 gene mutations in Polish patients with the early-onset form of Parkinson disease. Parkinsonism Relat. Disord., 2010, 16, 136-138.
177. Li, X.; Kitami, T.; Wang, M.; Mizuno, Y.; Hattori, N. Geographic and ethnic differences in frequencies of two polymorphisms (D/N394 and L/I272) of the parkin gene in sporadic Parkinson's disease. Parkinsonism Relat. Disord., 2005, 11, 485-491.
178. Kay, D.M.; Moran, D.; Moses, L.; Poorkaj, P.; Zabetian, C.P.; Nutt, J.; Factor, S.A.; Yu, C.E.; Montimurro, J.S.; Keefe, R.G.; Schellenberg, G.D.; Payami, H. Heterozygous parkin point mutations are as common in control subjects as in Parkinson's patients. Ann. Neurol., 2007, 61, 47-54.
179. Bardien, S.; Keyser, R.; Yako, Y.; Lombard, D.; Carr, J. Molecular analysis of the parkin gene in South African patients diagnosed with Parkinson's disease. Parkinsonism Relat. Disord., 2009, 15, 116-121.
180. Chung, K.K.;Zhang, Y.; Lim, K.L.; Tanaka, Y.; Huang, H.; Gao, J.; Ross, C.A.; Dawson, V.L.; Dawson, T.M. Parkin ubiquitinates the alpha-synuclein-interacting protein.; synphilin-1: implications for Lewy-body formation in Parkinson disease. Nat. Med., 2001, 7, 1144-1150.
181. Cookson, M.R. Neurodegeneration: how does parkin prevent Parkinson's disease? Curr Biol., 2003, 13(13), 522-524.
182. Sunada, Y.; Saito, F.; Matsumura, K.; Shimizu, T. Differential expression of the parkin gene in the human brain and peripheral leukocytes. Neurosci. Lett., 1998, 254(3), 180-182.
183. Exner, N.; Treske, B.; Paquet, D.; Holmström, K.; Schiesling, C.; Gispert, S.; Carballo-Carbajal, I.; Berg, D.; Hoepken, H.H.; Gasser, T.; Krüger, R.; Winklhofer, K.F.; Vogel, F.; Reichert, A.S.; Auburger, G.; Kahle, P.J.; Schmid, B.; Haass, C. Loss-of-function of human PINK1 results in mitochondrial pathology and can be rescued by parkin. J. Neurosci., 2007, 27(45), 12413-12418.
184. Berger, A.K.; Cortese, G.P.; Amodeo, K.D.; Weihofen, A.; Letai, A.; LaVoie, M.J. Parkin selectively alters the intrinsic threshold for mitochondrial cytochrome c release. Hum. Mol. Genet., 2009, 18(22), 4317-4328.
185. Narendra, D.; Tanaka, A.; Suen, D.F.; Youle RJ Parkin-induced mitophagy in the pathogenesis of Parkinson disease. Autophagy., 2009, 5(5), 706-708.
186. Schlehe, J.S.; Lutz, A.K.; Pilsl, A.; Lämmermann, K.; Grgur, K.; Henn, I.H.; Tatzelt, J.; Winklhofer, K.F. Aberrant folding of pathogenic Parkin mutants: aggregation versus degradation. J Biol Chem., 2008, 283(20), 13771-13779.
187. Lohmann, E.; Periquet, M.; Bonifati, V.; Wood, NW.; De Michele, G.; Bonnet, A.M.; Fraix V.; Broussolle E.; Horstink M.W.; Vidailhet M.; Verpillat P.; Gasser T.; Nicholl D.; Teive H.; Raskin S.; Rascol O.; Destée A.; Ruberg M.; Gasparini F.; Meco G.; Agid Y.; Durr A.; Brice A. How much phenotypic variation can be attributed to parkin genotype? Ann. Neurol., 2003, 54, 176-185.
188. Bonifati, V. Autosomal recessive parkinsonism. Parkinsonism Relat. Disord., 2012, 18S1, 4-6.
189. Benbunan, B.R.; Korczyn, A.D.; Giladi, N. Parkin mutation associated parkinsonism and cognitive decline.; comparison to early onset Parkinson's disease. J. Neural. Transm., 2004, 111(1), 47-57.
190. Nisipeanu, P.; Inzelberg, R.; Blumen, S.C.; Carasso, R.L.; Hattori, N.; Matsumine, H.; Mizuno, Y. Autosomal-recessive juvenile parkinsonism in a Jewish Yemenite kindred: mutation of Parkin gene. Neurology, 1999, 53(7), 1602-1604.